Literature DB >> 23062421

TNM staging of colorectal carcinoma: issues and caveats.

Jinru Shia1, David S Klimstra, Pelin Bagci, Olca Basturk, N Volkan Adsay.   

Abstract

The TNM staging system of the American Joint Committee on Cancer and the Union for International Cancer Control provides the most reliable guidelines for the prognostication and treatment of colorectal carcinoma. However, issues and caveats exist in the application of this system, mostly relating to the definition of the staging parameters and the pathologic interpretation of the gross and microscopic findings of the resected specimens. This article highlights some of the major issues in both areas. First, it assesses the definition of selected staging parameters, including pTis, pT4a versus pT4b, tumor deposits/N1c, ypT/ypN, and the TNM for rectal versus anal carcinoma. Second, it discusses major problematic areas in the pathologic interpretation of "pseudoinvasion" versus true invasion, deep pT2 versus superficial pT3, serosal involvement, radial margin, total mesorectal excision specimens, and postneoadjuvant chemoradiation rectal resections. The article also provides a brief discussion about some of the major adjunct histopathologic prognostic factors, such as medullary-type histology and tumor differentiation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23062421     DOI: 10.1053/j.semdp.2012.02.001

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  9 in total

Review 1.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

Review 2.  Evolving notions on immune response in colorectal cancer and their implications for biomarker development.

Authors:  Fabio Grizzi; Gianluca Basso; Elena Monica Borroni; Tommaso Cavalleri; Paolo Bianchi; Sanja Stifter; Maurizio Chiriva-Internati; Alberto Malesci; Luigi Laghi
Journal:  Inflamm Res       Date:  2018-01-10       Impact factor: 4.575

3.  HLA-G as a prognostic marker in stage II/III colorectal cancer: not quite there yet.

Authors:  Federica Grillo; Luca Mastracci; Alessandro Gambella; Stefano Scabini; Gabriele Zoppoli; Annalisa De Silvestri; Simona Pigozzi; Michele Paudice; Michela Campora; Roberto Fiocca
Journal:  Histochem Cell Biol       Date:  2022-07-28       Impact factor: 2.531

4.  MicroRNA-539 inhibits colorectal cancer progression by directly targeting SOX4.

Authors:  Jian Zhao; Jian Xu; Rui Zhang
Journal:  Oncol Lett       Date:  2018-06-04       Impact factor: 2.967

5.  Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer.

Authors:  Başak Varol; Özlem Coşkun; Senem Karabulut; Kürşat Rahmi Serin; Oktar Asoğlu; Işıl Albeniz; Faruk Taş; Rüstem Nurten
Journal:  Tumour Biol       Date:  2014-02-18

6.  Descending colo-colonic intussusception secondary to signet ring cell carcinoma: A case report.

Authors:  Ke-Kang Sun; Dong Yang; Mingqiang Gan; Xiao-Yang Wu
Journal:  Oncol Lett       Date:  2014-12-17       Impact factor: 2.967

7.  Adjuvant Radiation Survival Benefits in Patients with Stage 1B Rectal Cancer: A Population-based Study from the Surveillance Epidemiology and End Result Database (1973-2010).

Authors:  Abdul Waheed; Frederick D Cason
Journal:  Cureus       Date:  2019-12-05

8.  Comparison of Long-Term Survival Outcomes of T4a and T4b Colorectal Cancer.

Authors:  Ji Ha Lim; Jung Wook Huh; Woo Yong Lee; Seong Hyeon Yun; Hee Cheol Kim; Yong Beom Cho; Yoon Ah Park; Jung Kyong Shin
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

9.  Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F-FDG PET/CT for Patients with Colorectal Cancer.

Authors:  Xin Liu; Kun Xiang; Guang-Yong Geng; Shi-Cun Wang; Ming Ni; Yi-Fan Zhang; Hai-Feng Pan; Wei-Fu Lv
Journal:  Contrast Media Mol Imaging       Date:  2022-01-30       Impact factor: 3.161

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.